VivoSeq
Other

Neonatal Respiratory Distress

5

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Neonatal respiratory distress is an early-stage landscape with 5 programs across 3 companies. The most active players are Pfizer, Eyegate Pharmaceuticals, Inc., Retrophin. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

ApprovedE

Eyegate Pharmaceuticals, Inc.

1 program

ApprovedR

Retrophin

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Unknown status2 · 50%
Completed1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000563
Dexamethasone Before Elective Cesarean Section at Term in Reducing Neonatal Respiratory Distress Syndrome
Unknown status·—·Phase 4·NCT04816097·950 enrolled
Surfactant for Neonatal Respiratory Distress Syndrome at High Altitude Areas:a Prospective Cohort Study
Unknown status·—·N/A·NCT03479450·200 enrolled
Diaphragmatic Activity During Constant or Variable Flow CPAP in Neonates: a Non-inferiority, Randomized, Alternating Treatments Trial
Recruiting·CCentre Hospitalier Intercommunal Creteil·Preclinical·NCT07513051·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)